A Phase 2b Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24, or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 weeks of Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic
ID Number 08-1147Principal Investigator(s)
Joseph A Odin
Department(s) or Division(s)
The purpose of this study is to compare the safety, tolerability and effectiveness of the experimental drug GS-9190 along with Peginterferon Alfa 2a (PEG) and Ribavirin (RIBA) compared to using only PEG and RIBA for treatment of chronic hepatitis C virus (HCV) infection.
Joseph A. Odin, MD
Recruiting Patients: No